<DOC>
	<DOC>NCT00998751</DOC>
	<brief_summary>The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.</brief_summary>
	<brief_title>A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Male or Female patients, age &gt;18 Life expectancy &gt; 6 months Histological proven, metastatic, or locally advanced and nonoperable, non pretreated GIST. Patients having never received any tyrosine kinase inhibitor, including as adjuvant therapy CKit (CD117) positive tumors detected immunohistochemically Measurable tumor lesions with longest diameter &gt;20 mm using conventional techniques or &gt;10 mm with spiral CT scan Documented allergy to the similar drug of AB1010 Inadequate organ function Patients with a history of any other malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>cKIT inhibitor</keyword>
	<keyword>GIST</keyword>
</DOC>